FREDERICK, Md., May 31, 2011 /PRNewswire/ -- SAIC-Frederick, Inc. and Biomatrica have begun a technology collaboration to improve molecular analysis of tumors, which is becoming increasingly important in cancer research and in the design of the next generation of targeted therapies.
The two organizations will focus on developing better processes to isolate nucleic acids from tumor samples collected by pathologists in the clinic. Preserving nucleic acids, particularly RNA, is important for correlating histology of tumor tissues and molecular analysis. Traditional methods for preserving these nucleic acids are not well adapted to the clinical setting, however, so their usefulness in research has been limited.
The collaboration was developed under the Advanced Technology Partnerships Initiative (ATPI) of the National Cancer Institute (NCI). SAIC-Frederick is the operations and technical support contractor for NCI's federal national laboratory in Frederick, Md., and facilitates partnerships for the ATPI, which aims to move basic research findings more rapidly into the clinic to benefit patients.
Under the collaboration, SAIC-Frederick researchers at the Laboratory Animal Sciences Program will explore integration of proprietary reagents from Biomatrica into molecular pathology workflows. The objective is to streamline processes while increasing efficiency and integrity of RNA isolated from histological samples in cancer studies.
"Our team continually explores better ways to conduct assays. This collaboration with Biomatrica may improve isolation of nucleic acids from histological samples, particularly very labile RNA molecules," said Larry Sternberg, Ph.D., Director of the Histology Section of the Laboratory Animal Sciences Program. Sternberg is employed by SAIC-Frederick, which operates the facility for NCI.
|SOURCE Biomatrica Inc.; SAIC-Frederick, Inc.|
Copyright©2010 PR Newswire.
All rights reserved